Teva Asks High Court to Block Generics Ahead of Copaxone Ruling

could usher in a new era of deference to trial judges in patent cases. But Teva's lawyers reminded the Supreme Court on Monday that there's real money at stake in the case as well.

YOUR COMPLIMENTARY 15-DAY LAW.COM TRIAL HAS ENDED.
Subscribe now to continue reading →

To continue reading, upgrade and become a Law.com subscriber.
Get 2 MONTHS FREE when you sign up for a 12 month subscription.